SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Ovarian cancer is a leading cause of cancer death in women in the United States. While the majority of ovarian cancers are serous, some rarer subtypes (i.e. clear cell) are often associated with ...
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...
The Ras/mitogen-activated protein kinase (MAPK) pathway is a central signalling cascade that transmits extracellular growth and differentiation cues to nuclear effectors. Germline mutations in ...
Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC). This is an ...
Erasca, Inc. announced significant progress in its RAS-targeting franchise, including the FDA's clearance of an investigational new drug application for ERAS-0015 and the submission of an IND ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results